We have previously demonstrated a blockade in NK cell development in mouse models of AML marked by failure to progress from stage 2 (CD27+CD11b−) to stage 3 (CD27+CD11b+) NK cells in the spleen [19]. This evidence concerns the gene ITGAM and acute myeloid leukemia.